218. Alport syndrome
16 clinical trials,   24 drugs   (DrugBank: 11 drugs),   5 drug target genes,   27 drug target pathways

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03373786
(ClinicalTrials.gov)
December 22, 201722/10/2017A Study of RG-012 in Subjects With Alport SyndromeA Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport SyndromeAlport SyndromeDrug: RG012Genzyme, a Sanofi CompanyNULLCompleted18 Years65 YearsAll4Phase 1United States
2EUCTR2016-002181-32-GB
(EUCTR)
07/12/201608/09/2016A research study to evaluate the safety and effectiveness of RG-012 as a treatment for patients with Alport syndromeA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Patients with Alport Syndrome - A Phase 2 Study to Evaluate Weekly RG012 Injections in Alport Syndrome Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Regulus Therapeutics Inc.NULLNot Recruiting Female: yes
Male: yes
30Phase 2France;United States;Canada;Spain;Australia;Germany;United Kingdom